nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.09.2014 | Letter to the Editor

Questionable role of adjuvant chemotherapy in rectal cancer patients who had reached pathological complete response after neoadjuvant concurrent chemoradiotherapy: no matter in the East or in the West

verfasst von: William Tzu-Liang Chen, Tao-Wei Ke, Chia-Chin Li, Chun-Ru Chien

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 9/2014

Einloggen, um Zugang zu erhalten

Excerpt

To the Editors, …

Capirci C, Valentini V, Cionini L et al (2008) Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys 72:99–107PubMedCrossRef

Chien CR, Shih YC (2013) Use of personalized decision analysis in decision making for palliative vs. surgical management of the oldest–old patients with localized skin cancer in a culturally sensitive environment: a case study of a 96-year-old male Taiwanese patient. J Pain Symptom Manage 45:792–797PubMedCrossRef

Geva R, Itzkovich E, Shamai S, Shacham-Shmueli E, Soyfer V, Klausner JM, Tulchinsky H (2014) Is there a role for adjuvant chemotherapy in pathological complete response rectal cancer tumors following neoadjuvant chemoradiotherapy? J Cancer Res Clin Oncol [Epub ahead of print]

Hsia TC, Tu CY, Chen HJ, Chien CR (2013) Effectiveness of intensity-modulated radiotherapy for lung cancer. Clin Oncol (R Coll Radiol) 25:447–448CrossRef

Ke TW, Liao YM, Chiang HC, Chang SC, Wang PH, Chen YY, Chen WT, Chien CR (2014) Effectiveness of neoadjuvant concurrent chemoradiotherapy versus up-front proctectomy in clinical stage II–III rectal cancer: a population-based study. Asia Pac J Clin Oncol. doi:10.1111/ajco.12172 PubMed

Lin CC, Hsia TC, Chien CR (2012) 3rd line Erlotinib for lung cancer in Asia may be as cost-effective as in the Western world. Lung Cancer 76:499–500PubMedCrossRef

Nelson VM, Benson AB 3rd (2013) Pathological complete response after neoadjuvant therapy for rectal cancer and the role of adjuvant therapy. Curr Oncol Rep 15:152–161PubMedCrossRef

Titel: Questionable role of adjuvant chemotherapy in rectal cancer patients who had reached pathological complete response after neoadjuvant concurrent chemoradiotherapy: no matter in the East or in the West
verfasst von: William Tzu-Liang Chen
Tao-Wei Ke
Chia-Chin Li
Chun-Ru Chien
Publikationsdatum: 01.09.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 9/2014
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-014-1749-5

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Questionable role of adjuvant chemotherapy in rectal cancer patients who had reached pathological complete response after neoadjuvant concurrent chemoradiotherapy: no matter in the East or in the West

Excerpt

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2014

BRCA1 promoter methylation is a marker of better response to platinum–taxane-based therapy in sporadic epithelial ovarian cancer

Positive association between circulating 25-hydroxyvitamin D levels and prostate cancer risk: new findings from an updated meta-analysis

Axitinib alone or in combination with chemotherapeutic drugs exerts potent antitumor activity against human gastric cancer cells in vitro and in vivo

The role of miR-148a in gastric cancer

IL-17F gene polymorphism is associated with susceptibility to acute myeloid leukemia

Low-grade dietary-related inflammation and survival after colorectal cancer surgery

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie